Vimarsana
Biggest News Aggregation in the World

Were Presented News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Were Presented. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Were Presented Today - Breaking & Trending Today

New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing - Vimarsana News

New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing

Diagnostic Evaluations Were Consistent With GalleriⓇ-Predicted Cancer Signal Origin in 78% of Study Participants Whole-Body Imaging Did Not Contribute to Di ...

Source: oilnow.gy
Stock Market | FinancialContent Business Page - Vimarsana News

Stock Market | FinancialContent Business Page

FinancialContent fully hosted finance channel

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) - Vimarsana News

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut - Vimarsana News

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acut

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La...

Oberwart - Bildungscampus: Details zur Planung präsentiert - Vimarsana News

Oberwart - Bildungscampus: Details zur Planung präsentiert

Das neue Oberwarter Gebäude soll Mittelpunkt eines Zentrums für Bildung, Kultur und Freizeit werden. Baustart soll im Herbst 2023 sein.

Source: bvz.at